Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
We are having a hard time with a media release issued yesterday by BJU International in relation to a study just published in that journal by Tewari et al. (Actually, we are having a hard time with the results of the study itself too.)
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: age, follow-up, orgasm, potency, RALP, sexual function | 4 Comments »
Data reported earlier this year from the PIVOT study and separately from the long-term Scandinavian study have shown that the surgical treatment of prostate cancer in the patients enrolled in these trials showed no median prostate-cancer specific or overall survival benefit compared to watchful waiting in patients of > 65 years of age.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", age, elderly, old, radical prostatectomy, RALP, robot-assisted | 2 Comments »
A new report in European Urology may offer some insights into the value of large, retrospective data analyses as compared to multi-center, randomized clinical trials when it comes to the assessment of the effects of different first-line treatments on the management of clinically localized prostate cancer.
Filed under: Management, Treatment, Uncategorized | Tagged: age, mortality, observation, radical prostatectomy, watchful waiting | 5 Comments »
A new analysis of data from a large, consecutive series of Swedish patients suggests a very strong correlation between age at time of radical prostatectomy and risk for significant, long-term urinary leakage.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: age, education, incontinence, radical prostatectomy, risk | Leave a Comment »
A recent article in the Journal of Urology offers some insight into the risk for a diagnosis of prostate cancer in a large, relatively young cohort of men undergoing regular health checks in the period between 1991 and 2008.
Filed under: Diagnosis, Management, Risk | Tagged: age, health, risk, U.S. Air Force | 2 Comments »
On March 29 we commented on a newly published paper by Drazer et al. dealing with prostate cancer testing in men of 70 years of age and older. Now this same issue has been taken up by Gina Kolata in an article in the New York Times that will certainly have wider reach than our [...]
Filed under: Diagnosis, Risk | Tagged: age, risk, screening, testing | 2 Comments »
The ability to identify men at high risk for — and subsequently with — more aggressive forms of prostate cancer relatively early in their lives is obviously an important goal. Younger men tend to recover better from initial treatment for localized prostate cancer than their older peers.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: age, military, outcome, young | Leave a Comment »
A new report in the Journal of Clinical Oncology suggests that — at least between 2000 and 2005 — “excessive PSA screening in elderly men with limited life expectancies” was a significant problem, and may remain so today.
Filed under: Diagnosis, Risk | Tagged: age, life expectancy, PSA, screening, testing | 2 Comments »
New data from Peter Albertsen and his colleagues at the University of Connecticut have emphasized the importance of thorough assessment of the health status and co-morbidities of older men who are diagnosed with prostate cancer before making decisions about appropriate management.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: age, Co-morbidity, mortality | Leave a Comment »
A new report from the Cleveland Clinic provides us with rigorous data on the acceptability and outcomes of active surveillance (AS) as a management strategy for men diagnosed with low-risk prostate cancer — regardless of their age at the time of diagnosis.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: acceptance, active surveillance, age, outcome | 1 Comment »
The proposed list of complications as a consequence of androgen deprivation therapy (ADT) for advanced prostate cancer has just been increased.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, age, androgen deprivation therapy, cataracts, risk | Leave a Comment »
A Dutch research group has compared survival after prostate brachytherapy in two sets of patients, one aged ≤ 60 years at time of treatment and the other aged >60 years.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 10-year, age, brachytherapy, outcome | 2 Comments »
Overall life expectancy of men in the US continues to rise. As a consequence, the way we treated localized prostate cancer in men of ≥ 70 years of age in 1990 will probably not be relevant or appropriate to the way we need to treat such men in 2020 (or perhaps even today).
Filed under: Uncategorized | Tagged: age, elderly, high, localized, risk, Treatment | 2 Comments »
A new article just published on-line in the Journal of Clinical Oncology is entitled “Impact of age at diagnosis on prostate cancer treatment and survival.”
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: age, outcome, risk, Treatment | Leave a Comment »
In early 2009 the European Randomized Study of Screening for Prostate Cancer (ESRPC) reported a reduction of 20 percent in prostate cancer-specific mortality in a screened cohort of men aged between 55 and 74 years of age — as opposed to an unscreened cohort with the same age constraints.
Filed under: Diagnosis, Risk | Tagged: age, mortality, outcomes, PSA, risk, screening | 12 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site